Abstract YO3
Case summary
METASTATIC BREAST CANCER TO ESOPHAGUS: A CASE REPORT AND REVIEW OF THE LITERATURE
Secondary esophageal carcinoma from a breast primary is an infrequent phenomenon occurring in around 0.4% of patients. It is pertinent to rule out esophageal metastasis when a patient of breast carcinoma present with dysphagia after a long DFS. Most esophageal metastasis are usually submucosal deposition, requiring EUS-FNB for diagnosis. Given the rarity of this presentation and failure of diagnosis by simple mucosal biopsy during patient’s lifetime, there is a general lack of consensus on management guidelines in these patients.
Herein we report a case of 65 year old female presented with dysphagia who was subsequently diagnosed with esophageal metastases, 14years post surgery for breast cancer. She was treated with a combination of systemic Chemotherapy, hormonal therapy and local radiotherapy comprising both external beam radiotherapy(EBRT) and Intraluminal radiotherapy(ILRT). We also performed a comprehensive review of literature on esophageal metastases from breast primary, aiming to improve the diagnostic accuracy and treatment efficacy in this rare presentation. Our patient tolerated the treatment well and achieved a significant symptomatic improvement post Radiotherapy. Reviewing various literature, we observed 83% patients presented with complaints of dysphagia after a median of 13 years post breast surgery, with 72% metastases involving mid thoracic esophagus while majority were hormonally receptive.
We conclude that patients presenting with dysphagia post breast cancer treatment, should undergo EUS-FNB to rule out esophageal metastasis. While surgical interventions were effective treatment in some cases, we suggest systemic Chemotherapy with Hormonal therapy, and radiotherapy for local control as the management of choice in these patients. Even though prognosis is difficult to predict , this combined modality of treatment seems to achieve a better overall survival.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
450P - Are grade III well-differentiated neuroendocrine tumours a unique clinic-pathological entity?
Presenter: Jahnavi Kalvala
Session: Poster viewing 06
451P - The activity and safety of anlotinib combined with chemotherapy for patients with desmoid tumor: A retrospective study in a single institution
Presenter: Peng Zhang
Session: Poster viewing 06
452P - Medical and paramedical students’ awareness of environmental risk factors for cancer
Presenter: Mostafa Behery
Session: Poster viewing 06
453P - Relationship between Interleukin-6 Levels (IL-6) and COVID-19 vaccination status in cancer patients at Dr. Moewardi General Hospital, Indonesia
Presenter: Rico Hutabarat
Session: Poster viewing 06
454P - To study the prevalence of lower limb deep vein thrombosis in patients who present with stage III/IV solid tissue malignancies in Indian patients
Presenter: Oshin Suri
Session: Poster viewing 06
455P - Succinate dehydrogenase deficient GIST: Case series and review of literature from a tertiary care centre in India
Presenter: Akhil Santhosh
Session: Poster viewing 06
456P - Outcomes of COVID-19 infection in cancer patients: A single center study
Presenter: Sindhu G
Session: Poster viewing 06
457P - The effect of Interleukin-6 (IL-6) on malignancy in COVID-19 patients in Dr. Moewardi General Hospital Surakarta
Presenter: Meirisa Ardianti
Session: Poster viewing 06
458P - A real-world depiction of difficulties in applicability of IO regimens into clinical practice in metastatic setting
Presenter: Sharat Chandra Goteti
Session: Poster viewing 06
460P - The role of fluorescence-based cell-free DNA assay for detection of cancer by comparing patients with and without cancer
Presenter: Jae-Joon Kim
Session: Poster viewing 06